Erratum: Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels (Journal of the American Medical Association (2012) 310, 17, (1829-1836) DOI: 10.1001/jama.2013.280386);Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels

JAMA

Volumn 310, Issue 17, 2013, Pages 1829-1836

  Vigen, Rebecca ^a   O'Donnell, Colin I ^b,c   Barón, Anna E ^b,c   Grunwald, Gary K ^b,c   Maddox, Thomas M ^b,c,d   Bradley, Steven M ^b,c,d   Barqawi, Al ^b,c   Woning, Glenn ^b,c   Wierman, Margaret E ^b,c   Plomondon, Mary E ^b,c,d   Rumsfeld, John S ^b,c,d   Ho, P Michael ^b,c,d  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d Colorado Cardiovascular Outcomes Research ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; TESTOSTERONE;

ADULT; ADVERSE OUTCOME; ANDROGEN THERAPY; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD PRESSURE; BRAIN ISCHEMIA; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; TESTOSTERONE BLOOD LEVEL; VETERAN;

EID: 84887056433     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.283704     Document Type: Erratum

References (40)

1. US Department of Food and Drug Administration. Reproductive Health Drugs Advisory Committee. http://www.fda.gov/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee. Updated July 31, 2012. Accessed on October 11, 2013.
2. US Securities and Exchange Commission. Annual report of Auxilium Pharmaceuticals Inc, Form 10-K. http://services.corporate-ir.net/SEC.Enhanced/ SecCapsule.aspx?c=142125&fid=8040442. Accessed May 3, 2013.
3. Spitzer M, Huang G, Basaria S, Travison TG, Bhasin S. Risks and benefits of testosterone therapy in older men. Nat Rev Endocrinol. 2013;9(7):414-424.
4. Bhasin S, Cunningham GR, Hayes FJ, et al Task Force, Endocrine Society. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(6):2536-2559.
5. Wang C, Swerdloff RS, Iranmanesh A, et al Testosterone Gel Study Group. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab. 2000;85(8):2839-2853.
6. Boloña ER, Uraga MV, Haddad RM, et al. Testosterone use in men with sexual dysfunction: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc. 2007;82(1):20-28.
7. Isidori AM, Giannetta E, Gianfrilli D, et al. Effects of testosterone on sexual function in men: results of ameta-analysis. Clin Endocrinol (Oxf). 2005;63(4):381-394.
8. Isidori AM, Giannetta E, Greco EA, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: ameta-analysis. Clin Endocrinol (Oxf). 2005;63(3):280-293.
9. Snyder PJ, Peachey H, Berlin JA, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab. 2000;85(8):2670-2677.
10. Sih R, Morley JE, Kaiser FE, Perry HM III, Patrick P, Ross C. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab. 1997;82(6):1661-1667.
11. Jones TH, Arver S, Behre HM, et al; TIMES2 Investigators. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care. 2011;34(4):828-837.
12. Jones TH, Saad F. The effects of testosterone on risk factors for, and the mediators of, the atherosclerotic process. Atherosclerosis. 2009;207(2):318-327.
13. Mårin P, Holmäng S, Gustafsson C, et al. Androgen treatment of abdominally obese men. Obes Res. 1993;1(4):245-251.
14. Mathur A, Malkin C, Saeed B, Muthusamy R, Jones TH, Channer K. Long-term benefits of testosterone replacement therapy on angina threshold and atheroma in men. Eur J Endocrinol. 2009;161(3):443-449.
15. Malkin CJ, Pugh PJ, Morris PD, et al. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart. 2004;90(8):871-876.
16. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363(2):109-122.
17. Box TL, McDonell M, Helfrich CD, Jesse RL, Fihn SD, Rumsfeld JS. Strategies from a nationwide health information technology implementation: the VA CART story. J Gen Intern Med. 2010;25(suppl 1):72-76.
18. Byrd JB, Vigen R, Plomondon ME, et al. Data quality of an electronic health record tool to support VA cardiac catheterization laboratory quality improvement: the VA Clinical Assessment, Reporting, and Tracking System for Cath Labs (CART) program. Am Heart J. 2013;165(3):434-440.
19. Wilson RF, Marcus ML, White CW. Prediction of the physiologic significance of coronary arterial lesions by quantitative lesion geometry in patients with limited coronary artery disease. Circulation. 1987;75(4):723-732.
20. Smith SC Jr, Feldman TE, Hirshfeld JWJr, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; American College of Cardiology/American Heart Association/Society for Cardiovascular Angiography and Interventions Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention. ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAIWriting Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation. 2006;113(1):156-175.
21. Cowper DC, Kubal JD, Maynard C, Hynes DM. A primer and comparative review of major US mortality databases. Ann Epidemiol. 2002;12(7):462-468.
22. Sohn M-W, Arnold N, Maynard C, Hynes DM. Accuracy and completeness of mortality data in the Department of Veterans Affairs. Popul Health Metr. 2006;4(1):2.
23. Xu S, Shetterly S, Powers D, et al. Extension of Kaplan-Meier methods in observational studies with time-varying treatment. Value Health. 2012;15(1):167-174.
24. Snapinn S, Jiang QI, Iglewicz B. Illustrating the impact of a time-varying covariate with an extended Kaplan-Meier estimator. Am Stat. 2005;59(4):301-307.
25. Haddad RM, Kennedy CC, Caples SM, et al. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc. 2007;82(1):29-39.
26. Fernández-Balsells MM, Murad MH, Lane M, et al. Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95(6):2560-2575.
27. Calof OM, Singh AB, Lee ML, et al. Adverse events associated with testosterone replacement in middle-aged and older men: ameta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci. 2005;60(11):1451-1457.
28. Shores MM, Smith NL, Forsberg CW, Anawalt BD, Matsumoto AM. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab. 2012;97(6):2050-2058.
29. Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol. 2008;167(4):492-499.
30. 2 receptor density and aggregation responses. Circulation. 1995;91(11):2742-2747.
31. Abbate R, Cioni G, Ricci I, Miranda M, Gori AM. Thrombosis and acute coronary syndrome. Thromb Res. 2012;129(3):235-240.
32. Death AK, McGrath KC, Sader MA, et al. Dihydrotestosterone promotes vascular cell adhesion molecule-1 expression in male human endothelial cells via a nuclear factor-kappaB-dependent pathway. Endocrinology. 2004;145(4):1889- 1897.
33. McCrohon JA, Jessup W, Handelsman DJ, Celermajer DS. Androgen exposure increases human monocyte adhesion to vascular endothelium and endothelial cell expression of vascular cell adhesion molecule-1. Circulation. 1999;99(17):2317-2322.
34. Pamukcu B, Lip GY, Devitt A, Griffiths H, Shantsila E. The role of monocytes in atherosclerotic coronary artery disease. Ann Med. 2010;42(6):394-403.
35. Hoyos CM, Killick R, Yee BJ, Grunstein RR, Liu PY. Effects of testosterone therapy on sleep and breathing in obese men with severe obstructive sleep apnea: a randomized placebo-controlled trial. Clin Endocrinol (Oxf). 2012;77(4):599-607.
36. Drager LF, Polotsky VY, Lorenzi-Filho G. Obstructive sleep apnea: an emerging risk factor for atherosclerosis. Chest. 2011;140(2):534-542.
37. Brambilla DJ, Matsumoto AM, Araujo AB, McKinlay JB. The effect of diurnal variation on clinical measurement of serum testosterone and other sex hormone levels in men. J Clin Endocrinol Metab. 2009;94(3):907-913.
38. Petersen LA, Wright S, Normand SL, Daley J. Positive predictive value of the diagnosis of acute myocardial infarction in an administrative database. J Gen Intern Med. 1999;14(9):555-558.
39. Niesner K, Murff HJ, Griffin MR, et al. Validation of VA administrative data algorithms for identifying cardiovascular disease hospitalization. Epidemiology. 2013;24(2):334-335.
40. Reker DM, Hamilton BB, Duncan PW, Yeh SC, Rosen A. Stroke: who's counting what? J Rehabil Res Dev. 2001;38(2):281-289.